Tagged with China

China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre.   COVID global emergency over but risks remain, says China health official (Reuters)…

China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…

Hong Kong In 2022, the biotech sector felt the impact of the challenges facing global capital markets and Hong Kong was no exception. Last year, only eight biotech companies listed on the Stock Exchange of Hong Kong Limited (HKEX), raising an aggregate of USD 473 million. Nonetheless, Hong Kong continues to serve…

China The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China, how the country’s drug pricing policy is impinging biotech profits, and the ways in which COVID-19 exposed the weaknesses in…

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

China A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s first personalised neoantigen-targeted cancer vaccine approval; the final green light for Sino Biopharm’s purchase of F-star, and AstraZeneca’s deal with…

China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…

China Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one of ups and downs as vaccine hesitancy and a slew of social issues have greatly affected uptake. But ultimately, this…

China A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric cancer partnership with CARsgen; Sino Biopharm’s continued attempt to buyout of F-star Therapeutics and Takeda’s deal with Hutchmed for a…

Taiwan In just 35 years, Taiwan has gone from having no biotechs on the TAIEX and Taiwan OTC stock exchanges to 124 listed firms with a combined market capitalization of more than USD 30 billion by 2020, as the below chart from the Carnegie Endowment for International Peace shows. In 2019,…

China The Chinese pharma market grew by eight percent from 2016 to 2018, slowed to four percent between 2018 and 2022 in part thanks to the introduction of volume-based procurement (VBP), and looks set to return to a healthier seven percent compound annual growth rate (CAGR) up to 2025 driven by…

China One of China’s leading vaccine manufacturers, CanSino Biologics has taken massive strides since its foundation in 2009 and has secured approvals in several countries for its ebola, meningitis, and COVID-19 jabs. The manufacturer of the world’s first inhaled COVID-19 vaccine, CanSinoBIO is also continuing to invest in mRNA technology in…